Company intelligence / Profile preview

Aeris Therapeutics

Woburn / Las Vegas*, Massachusetts / Nevada*, USAmarketscreener.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aeris developed the AeriSeal System—a foam-based lung sealant for minimally invasive treatment of advanced emphysema. The product received CE mark approval in Europe and Israel. Several clinical trials were conducted in the US and Europe, including pivotal Phase III studies. Some trials were terminated or withdrawn before completion. The technology was acquired by Pulmonx to complement their Zephyr Endobronchial Valve portfolio.

Therapeutic areas: Pulmonology
Modalities: Device-based therapy (foam-based lung sealant system)Inhaled drugs/biologics for pulmonary delivery
Industry: Therapeutic Medical Devices

Partnerships

Pulmonx Corporation post-acquisition; previously NIH/SBIR funding partners.

Beyond the preview

Go deeper on Aeris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeris Therapeutics.

Explore the full profile